Skip to main content

Table 1 Basic characteristics and NGS examination of four patients

From: Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

 

Patient 1

Patient 2

Patient 3

Patient 4

Age

62

60

59

67

Gender

male

female

female

male

Race

Asian

Asian

Asian

Asian

TNM stage

IV

IV

IV

IIIB

Pathology

Moderately differentiated adenocarcinoma

Invasive adenocarcinoma

Poorly differentiated adenocarcinoma

Invasive adenocarcinoma

EGFR-TKIs

Gefitinib

Gefitinib

Gefitinib

Gefitinib

Regimen

250 mg, qd

250 mg, qd

250 mg, qd

250 mg, qd

PFS (months)

5.2

6.9

8.1

5.1

Genomic alterations

EGFR Exon 21 L858R

MDM2 Amplification

TP53 D208G

ERBB4 L770V

BLM D997N

EGFR Exon 19 Deletion

MDM2 Amplification

CDK4 Amplification

ARID1B Q1312K

NKX2–1 G115S

PTCH1 G1136

RET R475W

EGFR Exon 19 Deletion

MDM2 Amplification

EGFR Amplification

CDK4 Amplification

CTIF R77L

APC L1564

EGFR Exon 21 L858R

MDM2 Amplification

FLT3 P336T

FYN L411M

FANCL M89I

NCOR1 P347T